Insulin Icodec: One Basal Injection a Week Instead of Every Day

The clinical scenario

Basal insulin has always meant a daily injection — 365 a year, indefinitely. For many people, especially those with type 2 diabetes starting insulin, that daily commitment is a barrier to getting started and staying consistent. Insulin icodec (Awiqli) reimagines the basal injection as a once-weekly event. This use case explains the concept; whether weekly dosing suits a given person is a clinical decision.

Why the mechanism fits

Icodec is a basal insulin engineered for a roughly one-week half-life. Two design elements make that possible:

• A long fatty-diacid side chain binds strongly but reversibly to albumin, the abundant carrier protein in blood, parking most of the injected insulin in an inactive reservoir that slowly releases free hormone.
• Amino-acid substitutions slow how quickly the insulin is cleared once it engages its receptor.

Together these create a large circulating buffer that trickles out steady basal insulin across seven days from a single dose — a natural extension of the slow-release strategy used in daily ultra-long insulins like degludec.

The standout feature: ~52 injections a year

The headline benefit is obvious: one injection a week instead of one a day, cutting basal injections from about 365 to about 52 per year. For people beginning basal insulin — a step often delayed by reluctance to inject daily — this can lower the barrier to starting and support better adherence over time. The once-weekly rhythm is simply easier to keep.

How it's given

Icodec is injected subcutaneously once weekly using a pen (a concentrated U-700 formulation keeps the weekly volume small), with a dedicated titration schedule to adjust the weekly dose to glucose readings. Its development program (the ONWARDS trials) studied it against daily basal insulins in both type 2 and type 1 diabetes.

The key safety consideration

A week-long insulin changes the safety picture in one important way: because a dose stays active for the whole week, a low blood sugar cannot be undone by skipping the next dose, the way it sometimes can with a daily insulin. To manage this, icodec uses a specific titration approach and dose-guidance tools, and glucose monitoring remains important. Hypoglycemia is still treated the usual way — fast carbohydrate, or a glucagon rescue if severe — but the long duration is a genuine factor in how it is used.

Approval status

Icodec is approved in the European Union, United Kingdom, Canada, Australia and several other regions. In the United States, the initial application received a complete response letter from the FDA, with particular attention to its use in type 1 diabetes — so availability and approved uses differ by country and should be checked locally.

It still only covers the background

Like all basal insulins, icodec addresses background needs only. People who also require mealtime coverage still use a rapid-acting insulin at meals, or other therapies. Weekly dosing simplifies the basal injection; it does not replace the whole regimen for everyone.

Realistic expectations

• Icodec is a convenience-focused basal insulin — its advantage is frequency, not a different kind of glucose control.
• The trade-off is a dose that persists for a week, requiring careful titration.
• It is not currently FDA-approved, though it is available in many other regions.

The takeaway

Insulin icodec applies the same albumin-binding chemistry that made ultra-long daily insulins possible, and pushes it to a full week — turning the daily basal injection into a weekly one. For the right person, especially someone starting basal insulin in type 2 diabetes, fewer injections can mean an easier start and steadier adherence, provided the week-long duration is respected in how it is dosed and monitored.

This article is educational and does not constitute medical advice. Insulin therapy is individualized and managed by a diabetes care team.